Biagio Pucci

Dr. Biagio Pucci

Mercogliano Laboratory, Istituto Nazionale Tumori—IRCCS—Fondazione G. Pascale, Napoli, Italy
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CCChiara Ciardiello
Chiara Ciardiello
ALAlessandra Leone
Alessandra Leone
PLPaola Lanuti
Paola Lanuti
MRmaria serena roca
maria serena roca
TMTania Moccia
Tania Moccia
Alfredo BudillonAlfredo Budillon
Alfredo Budillon
Molecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as “Large Oncosomes” (LO), have been identified in highly migratory and invasive PCa cells. We recently developed and characterized the DU145R80 subline, selected from parental DU145 cells as resistant to inhibitors of mevalonate pathway. DU145R80 showed different proteomic profile compared to parental DU145 cells, along with altered cytoskeleton dynamics and a more aggressive phenotype. Immunofluorescence staining and western blotting were used to identify blebbing and EVs protein cargo. EVs, purified by gradient ultra-centrifugations, were analyzed by tunable resistive pulse sensing and multi-parametric flow cytometry approach coupled with high-resolution imaging technologies. LO functional effects were tested in vitro by adhesion and invasion assays and in vivo xenograft model in nude mice. Xenograft and patient tumor tissues were analyzed by immunohistochemistry. We found spontaneous blebbing and increased shedding of LO from DU145R80 compared to DU145 cells. LO from DU145R80, compared to those from DU145, carried increased amounts of key-molecules involved in PCa progression including integrin alpha V (αV-integrin). By incubating DU145 cells with DU145R80-derived LO we demonstrated that αV-integrin on LO surface was functionally involved in the increased adhesion and invasion of recipient cells, via AKT. Indeed either the pre-incubation of LO with an αV-integrin blocking antibody, or a specific AKT inhibition in recipient cells are able to revert the LO-induced functional effects. Moreover, DU145R80-derived LO also increased DU145 tumor engraftment in a mice model. Finally, we identified αV-integrin positive LO-like structures in tumor xenografts as well as in PCa patient tissues. Increased αV-integrin tumor expression correlated with high Gleason score and lymph node status. Overall, this study is the first to demonstrate the critical role of αV-integrin positive LO in PCa aggressive features, adding new insights in biological function of these large EVs and suggesting their potential use as PCa prognostic markers.

15 April 2008 in Nucleic Acids Research
Verified
Journal Article
Open access
WLW. Liu
W. Liu
BPBiagio Pucci
Biagio Pucci
MRM. Rossi
M. Rossi
FPFrancesca M. Pisani
Francesca M. Pisani
RLR. Ladenstein
R. Ladenstein
The Mini-Chromosome Maintenance (MCM) proteins are candidates of replicative DNA helicase in eukarya and archaea. Here we report a 2.8 A crystal structure of the N-terminal domain (residues 1-268) of the Sulfolobus solfataricus MCM (Sso MCM) protein. The structure reveals single-hexameric ring-like architecture, at variance from the protein of Methanothermobacter thermoautotrophicus (Mth). Moreover, the central channel in Sso MCM seems significantly narrower than the Mth counterpart, which appears to more favorably accommodate single-stranded DNA than double-stranded DNA, as supported by DNA-binding assays. Structural analysis also highlights the essential role played by the zinc-binding domain in the interaction with nucleic acids and allows us to speculate that the Sso MCM N-ter domain may function as a molecular clamp to grasp the single-stranded DNA passing through the central channel. On this basis possible DNA unwinding mechanisms are discussed.

11 May 2018 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
PDF file
FIFederica Iannelli
Federica Iannelli
RLRita Lombardi
Rita Lombardi
MMMaria R. Milone
Maria R. Milone
BPBiagio Pucci
Biagio Pucci
SRSimona De Rienzo
Simona De Rienzo
FBFrancesca Bruzzese
Francesca Bruzzese
Background: Modifications of lipid metabolism have been progressively accepted as a hallmark of tumor cells and in particular, an elevated lipogenesis has been described in various types of cancers. Objective: Important or deregulated activity of the mevalonate pathway has been demonstrated in different tumors and a wide range of studies have suggested that tumor cells are more dependent on the unceasing availability of mevalonate pathway metabolites than their non-malignant complements. Methods: This study provides an overview of the state of the art of statins treatment on human cancer. Results: In recent times, various actions have been proposed for statins in different physiological and pathological conditions beyond anti-inflammation and neuroprotection activity. Statins have been shown to act through mevalonate-dependent and -independent mechanisms able to affect several tissue functions and modulating specific signal transduction pathways that could account for statin pleiotropic effect. Based on their characteristics, statins represent ideal candidates for repositioning in cancer therapy. Conclusion: In this review article, we provide an overview of the current preclinical and clinical status of statins as antitumor agents. In addition, we evaluated various patents that describe the role of mevalonate pathway inhibitors and methods to determine if cancer cells are sensitive to statins treatment.

1 September 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ARAnnapina Russo
Annapina Russo
DPDiogo Silva Pellosi
Diogo Silva Pellosi
VPValentina Pagliara
Valentina Pagliara
MMMaria Rita Milone
Maria Rita Milone
BPBiagio Pucci
Biagio Pucci
Fabiana QuagliaFabiana Quaglia
Fabiana Quaglia

25 February 2016 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TCTommaso Colangelo
Tommaso Colangelo
GPGiovanna Polcaro
Giovanna Polcaro
PZP Ziccardi
P Ziccardi
BPBiagio Pucci
Biagio Pucci
LML Muccillo
L Muccillo
VCVittorio Colantuoni
Vittorio Colantuoni
Impairment of the immune response and aberrant expression of microRNAs are emerging hallmarks of tumour initiation/progression, in addition to driver gene mutations and epigenetic modifications. We performed a preliminary survey of independent adenoma and colorectal cancer (CRC) miRnoma data sets and, among the most dysregulated miRNAs, we selected miR-27a and disclosed that it is already upregulated in adenoma and further increases during the evolution to adenocarcinoma. To identify novel genes and pathways regulated by this miRNA, we employed a differential 2DE-DIGE proteome analysis. We showed that miR-27a modulates a group of proteins involved in MHC class I cell surface exposure and, mechanistically, demonstrated that calreticulin is a miR-27a direct target responsible for most downstream effects in epistasis experiments. In vitro miR-27a affected cell proliferation and angiogenesis; mouse xenografts of human CRC cell lines expressing different miR-27a levels confirmed the protein variations and recapitulated the cell growth and apoptosis effects. In vivo miR-27a inversely correlated with MHC class I molecules and calreticulin expression, CD8+ T cells infiltration and cytotoxic activity (LAMP-1 exposure and perforin release). Tumours with high miR-27a, low calreticulin and CD8+ T cells' infiltration were associated with distant metastasis and poor prognosis. Our data demonstrate that miR-27a acts as an oncomiRNA, represses MHC class I expression through calreticulin downregulation and affects tumour progression. These results may pave the way for better diagnosis, patient stratification and novel therapeutic approaches.

1 April 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BPBiagio Pucci
Biagio Pucci
MFMariarita De Felice
Mariarita De Felice
MRMonia Rocco
Monia Rocco
FEFrancesco Esposito
Francesco Esposito
MFMariarosaria De Falco
Mariarosaria De Falco
FPFrancesca M. Pisani
Francesca M. Pisani
Mini-chromosome maintenance (MCM) proteins form ring-like hexameric complexes that are commonly believed to act as the replicative DNA helicase at the eukaryotic/archaeal DNA replication fork. Because of their simplified composition with respect to the eukaryotic counterparts, the archaeal MCM complexes represent a good model system to use in analyzing the structural/functional relationships of these important replication factors. In this study the domain organization of the MCM-like protein from Sulfolobus solfataricus (Sso MCM) has been dissected by trypsin partial proteolysis. Three truncated derivatives of Sso MCM corresponding to protease-resistant domains were produced as soluble recombinant proteins and purified: the N-terminal domain (N-ter, residues 1–268); a fragment comprising the AAA+ and C-terminal domains (AAA+-C-ter, residues 269–686); and the C-terminal domain (C-ter, residues 504–686). All of the purified recombinant proteins behaved as monomers in solution as determined by analytical gel filtration chromatography, suggesting that the polypeptide chain integrity is required for stable oligomerization of Sso MCM. However, the AAA+-C-ter derivative, which includes the AAA+ motor domain and retains ATPase activity, was able to form dimers in solution when ATP was present, as analyzed by size exclusion chromatography and glycerol gradient sedimentation analyses. Interestingly, the AAA+-C-ter protein could displace oligonucleotides annealed to M13 single-stranded DNA although with a reduced efficiency in comparison with the full-sized Sso MCM. The implications of these findings for understanding the DNA helicase mechanism of the MCM complex are discussed.